Vice President Corporate Development, Gilead Sciences
Dr. Jeremy Bender is Vice President of Corporate Development at Gilead. He joined Gilead from Tizona Therapeutics, where he was Chief Operating Officer responsible for the company’s finance, operations, alliance, and corporate development activities.
Prior to Tizona, Dr. Bender was Chief Business Officer of Sutro Biopharma, where he was responsible for business development, alliance and project management, external communications, and intellectual property strategy. During his time at Sutro, he completed partnering transactions with Celgene Corporation and EMD Serono providing more than $150M in non-dilutive capital. Dr. Bender received his undergraduate degree in Biological Sciences from Stanford University and his Ph.D.in Microbiology & Immunology from the University of Colorado, where he worked on peripheral T-cell selection in the labs of Philippa Marrack and John Kappler. He also received an M.B.A. from the MIT Sloan School of Management.